Zhonghua Zhong Liu Za Zhi. 2024 Jan 23;46(1):40-47. doi: 10.3760/cma.j.cn112152-20231130-00344.
Malignant pleural effusion (MPE) can occur in nearly all types of malignant tumors, with lung cancer being the most prevalent cause. The presence of MPE indicates an advanced stage or distant spread of the tumor, significantly reducing the patient's life expectancy. Particularly, a substantial amount of pleural effusion can impede heart and lung function, impair blood oxygen perfusion levels in the body, and greatly diminish patients' quality of life. Even when systemic treatment has alleviated the primary lung tumor in some patients, effective control over MPE remains challenging and impacts clinical outcomes. Therefore, it is crucial to implement measures for reducing or managing MPE while ensuring standardized treatment for lung cancer. In recent years, significant advancements have been made in diagnosing and treating lung cancer complicated by MPE through extensive basic and clinical research. Based on existing evidence and China's clinical practice experience, relevant experts from the China Association of Health Promotion and Education and Cancer Rehabilitation and Palliative Treatment Professional Committee of China Anti-Cancer Association (CRPC) have summarized key aspects related to diagnosis and treatment consensus opinions for lung cancer complicated by MPE. This aims to establish standardized procedures that will serve as a reference for doctors' clinical practice.
恶性胸腔积液（MPE）几乎可发生于所有类型的恶性肿瘤，其中肺癌是最常见的病因。MPE的出现表明肿瘤已处于晚期或发生远处转移，会显著缩短患者的预期寿命。特别是大量胸腔积液会妨碍心肺功能，损害体内血液氧灌注水平，极大降低患者的生活质量。即使在一些患者中全身治疗已缓解了原发性肺癌，但有效控制MPE仍然具有挑战性，并影响临床结局。因此，在确保肺癌规范化治疗的同时，采取措施减少或管理MPE至关重要。近年来，通过广泛的基础和临床研究，在诊断和治疗合并MPE的肺癌方面取得了显著进展。基于现有证据和中国的临床实践经验，中国健康促进与教育协会和中国抗癌协会癌症康复与姑息治疗专业委员会（CRPC）的相关专家总结了合并MPE的肺癌诊断和治疗共识意见的关键方面。目的是建立标准化程序，为医生的临床实践提供参考。
